[1]苏 坤,徐培培.清金化痰汤加减联合化疗对晚期肺癌患者中医症状积分及血清CYFRA21-1水平的影响[J].陕西中医杂志,2024,(4):511-515.[doi:DOI:10.3969/j.issn.1000-7369.2024.04.017]
点击复制

清金化痰汤加减联合化疗对晚期肺癌患者中医症状积分及血清CYFRA21-1水平的影响
分享到:

《陕西中医》杂志[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2024年4期
页码:
511-515
栏目:
临床研究
出版日期:
2024-04-05

文章信息/Info

作者:
苏 坤徐培培
(宿迁市中医院肿瘤科,江苏 宿迁 223800)
关键词:
非小细胞肺癌 清金化痰汤 化疗 细胞角蛋白19片段抗原21-1 免疫功能 痰热壅肺证
分类号:
R 734.2
DOI:
DOI:10.3969/j.issn.1000-7369.2024.04.017
文献标志码:
A
摘要:
目的:观察清金化痰汤加减联合化疗对Ⅲ、Ⅳ期痰热壅肺证非小细胞肺癌(NSCLC)患者的临床疗效。方法:采用随机数字表法将160例NSCLC患者分为对照组与联合组,每组80例。对照组予以长春瑞滨+顺铂(NP)化疗方案,联合组在NP化疗方案基础上联合清金化痰汤加减治疗。观察两组患者临床疗效、中医症状评分、免疫功能、肿瘤标志物水平及生存时间等指标的差异。结果:联合组患者的客观缓解率明显高于对照组(P<0.05)。治疗后,与对照组相比,联合组患者咳嗽、咳痰、胸闷、胸胁胀痛、倦怠乏力症状的积分显著更低(均P<0.05),血清肿瘤标志物细胞角蛋白19片段抗原21-1(CYFRA21-1)、神经元特异性烯醇化酶(NSE)、鳞状细胞癌抗原(SCCAg)的水平显著降低(均P<0.05)。治疗后,与对照组相比,联合组患者NK细胞、CD4+T细胞及CD3+T细胞的比例明显升高(均P<0.05)。与对照组相比,联合组患者Ⅱ级骨髓抑制及恶心呕吐的发生率显著较低(P<0.05)。对照组与联合组患者的中位总体生存时间(OS)分别为19.6、26.3个月; 中位无病生存时间(DFS)分别为12.7、14.1个月,联合组患者的OS优于对照组(P<0.05),两组DFS比较差异无统计学意义(P>0.05)。结论:清金化痰汤加减联合化疗治疗可有效改善NSCLC患者中医症状,提高治疗效果,减少化疗药物引起的不良反应。

参考文献/References:

[1] XIANG Y,GUO Z,ZHU P,et al.Traditional Chinese medicine as a cancer treatment:Modern perspectives of ancient but advanced science[J].Cancer Medicine,2019,8(5):1958-1975.
[2] 孟璠璐,刘瑜,程轩,等.小细胞肺癌药物治疗研究进展[J].陕西医学杂志,2022,51(10):1313-1317.
[3] DONG J,ZHANG R Y,SUN N,et al.Bio-inspired nanovilli chips for enhanced capture of tumor-derived extracellular vesicles:Toward non-invasive detection of gene alterations in non-small cell lung cancer[J].ACS Applied Materials & Interfaces,2019,11(15):13973-13983.
[4] 陈香梅,刘太锋,杨明,等.复方苦参注射液联合化疗治疗非小细胞肺癌疗效研究[J].陕西中医,2021,42(12):1700-1702.
[5] 张羽飞,朱鸿帆,吴申,等.复方皂刺汤联合PP方案治疗晚期非小细胞肺癌疗效及安全性分析[J].陕西中医,2020,41(1):60-62.
[6] GAO C,ZHUANG J,ZHOU C,et al.Prognostic value of aberrantly expressed methylation gene profiles in lung squamous cell carcinoma:A study based on the cancer genome atlas[J].Journal of Cellular Physiology,2019,234(5):6519-6528.
[7] SHENG H,LI Z,SU S,et al.YTH domain family 2 promotes lung cancer cell growth by facilitating 6-phosphogluconate dehydrogenase mRNA translation[J].Carcinogenesis,2020,41(5):541-550.
[8] WANG L,LI X,REN Y,et al.Cancer-associated fibroblasts contribute to cisplatin resistance by modulating ANXA 3 in lung cancer cells[J].Cancer Science,2019,110(5):1609-1620.
[9] YIN L,LIN X,LI N,et al.Evaluation of the global leadership initiative on malnutrition criteria using different muscle mass indices for diagnosing malnutrition and predicting survival in lung cancer patients[J].Journal of Parenteral and Enteral Nutrition,2021,45(3):607-617.
[10] ZHOU L,JIANG Y,LIU X,et al.Promotion of tumor-associated macrophages infiltration by elevated neddylation pathway via NF-κB-CCL2 signaling in lung cancer[J].Oncogene,2019,38(29):5792-5804.
[11] QU J,MEI Q,CHEN L,et al.Chimeric antigen receptor(CAR)-T-cell therapy in non-small-cell lung cancer(NSCLC):Current status and future perspectives[J].Cancer Immunology,2021,70(3):619-631.
[12] KURUPPU A I,PARANAGAMA P,GOONASEKARA C L.Medicinal plants commonly used against cancer in traditional medicine formulae in Sri Lanka[J].Saudi Pharmaceutical Journal,2019,27(4):565-573.
[13] WEN S,DAI L,WANG L,et al.Genomic signature of driver genes identified by target next-generation sequencing in Chinese non-small cell lung cancer[J].Oncologist,2019,24(11):e1070-e1081.
[14] KHAN A,SIDDIQUI S,HUSAIN S A,et al.Phytocompounds targeting metabolic reprogramming in cancer:An assessment of role,mechanisms,pathways,and therapeutic relevance[J].Journal of Agricultural and Food Chemistry,2021,69(25):6897-6928.
[15] JIANG M,ZHENG S.Geniposide inhibits non-small cell lung cancer cell migration and angiogenesis by regulating PPARγ/VEGF-A pathway[J].Quality Assurance and Safety of Crops & Foods,2022,14(1):46-54.
[16] ZHANG L,LING Z,HU Z,et al.Huanglian Jiedu decoction as an effective treatment for oral squamous cell carcinoma based on network pharmacology and experimental validation[J].Cancer Cell International,2021,21(1):1-26.
[17] SUN X,ROUDI R,DAI T,et al.Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer:A PRISMA systematic review and meta-analysis[J].BMC Cancer,2019,19(1):1-13.
[18] LI C,LV Y,SHAO C,et al.Tumor-derived exosomal lncRNA GAS5 as a biomarker for early-stage non-small-cell lung cancer diagnosis[J].Journal of Cellular Physiology,2019,234(11):20721-20727.
[19] JIANG Z B,WANG W J,XU C,et al.Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer[J].Cancer Letters,2021,515:36-48.
[20] ZHANG T,MA L,WU P,et al.Gallic acid has anticancer activity and enhances the anticancer effects of cisplatin in nonsmall cell lung cancer A549 cells via the JAK/STAT3 signaling pathway[J].Oncology Reports,2019,41(3):1779-1788.
[21] YANG L,DONG Y,LI Y,et al.IL-10 derived from M2 macrophage promotes cancer stemness via JAK1/STAT1/NF-κB/Notch1 pathway in non-small cell lung cancer[J].International Journal of Cancer,2019,145(4):1099-1110.
[22] LI Y,YAN H,XU X,et al.Erastin/sorafenib induces cisplatinresistant nonsmall cell lung cancer cell ferroptosis through inhibition of the Nrf2/xCT pathway[J].Oncology Letters,2020,19(1):323-333.
[23] 张珊,任小平,田应选.老年肺癌患者心理痛苦现状调查及影响因素分析[J].陕西医学杂志,2021,50(2):245-247,250.
[24] FU J,LV Y,JIA Q,et al.Dual-mixed/CMC model for screening target components from traditional Chinese medicines simultaneously acting on EGFR & FGFR4 receptors[J].Talanta,2019,192:248-254.
[25] BI M,ZHAO Z,YANG J,et al.Comparison of case-based learning and traditional method in teaching postgraduate students of medical oncology[J].Medical Teacher,2019,41(10):1124-1128.

相似文献/References:

[1]刘月芬,刘小红,于明军,等.清金化痰汤治疗非小细胞肺癌临床研究[J].陕西中医杂志,2019,(2):229.
 LIU Yuefen,LIU Xiaohong,YU Mingjun,et al.Clinical observation of nonsmall cell lung cancer patients treated with Qingjin Huatan decoction[J].,2019,(4):229.
[2]陈姣红,古红莉,员建中,等.参术扶正抗癌汤联合化疗及三维适形放疗对晚期非小细胞肺癌患者 血清T细胞亚群水平及生存质量的影响*[J].陕西中医杂志,2019,(5):564.
[3]张栓宝,严宁娟△,张燕平.复方斑蝥胶囊对非小细胞肺癌患者围术期血清炎症因子及免疫功能的影响[J].陕西中医杂志,2019,(7):890.
[4]任宝中,李 媛△.益气化瘀方配合化疗治疗晚期非小细胞肺癌临床研究*[J].陕西中医杂志,2019,(8):1036.
 REN Baozhong,LI Yuan..Application effect of TP chemotherapy Plus Yiqi Huayu decoction in advanced Non-small cell lung cancer patients[J].,2019,(4):1036.
[5]任东峰,孙国芳△.六君祛痰解毒汤联合化疗治疗非小细胞肺癌疗效〖JZ〗及对患者血管内皮生长因子的影响[J].陕西中医杂志,2020,(1):63.
[6]刘 婷,李 洋,石志红.灯盏花素对非小细胞肺癌A549细胞的作用及机制研究[J].陕西中医杂志,2021,(10):1363.[doi:DOI:10.3969/j.issn.1000-7369.2020.10.009]
 LIU Ting,LI Yang,SHI Zhihong.Effects of breviscapine on proliferation and apoptosis of non-small cell lung cancer A549 cells[J].,2021,(4):1363.[doi:DOI:10.3969/j.issn.1000-7369.2020.10.009]
[7]肖 凌,王 洋,钱建新,等.生脉饮合沙参麦冬汤联合西药治疗晚期非小细胞肺癌疗效研究[J].陕西中医杂志,2021,(12):1696.[doi:DOI:10.3969/j.issn.1000-7369.2020.12.010]
[8]陈香梅,刘太锋,杨 明,等.复方苦参注射液联合化疗治疗非小细胞肺癌疗效研究[J].陕西中医杂志,2021,(12):1700.[doi:DOI:10.3969/j.issn.1000-7369.2020.12.011]
[9]王理槐,孙银辉,张领兄,等.基于Wnt/β-catenin信号通路探讨血府逐瘀汤在非小细胞肺癌EGFR-TKI获得性耐药中的作用[J].陕西中医杂志,2022,(4):427.[doi:DOI:10.3969/j.issn.1000-7369.2022.04.004]
 WANG Lihuai,SUN Yinhui,ZHANG Lingxiong,et al.Efficacy of Xuefu Zhuyu decoction in EGFR-TKI-Acquired resistance of non-small cell lung carcinoma based on the Wnt/β-catenin signaling pathway[J].,2022,(4):427.[doi:DOI:10.3969/j.issn.1000-7369.2022.04.004]
[10]屈 直,王 芬,李志明,等.二陈汤对Lewis肺癌移植瘤生长及Hedgehog通路蛋白表达的影响[J].陕西中医杂志,2022,(5):555.[doi:DOI:10.3969/j.issn.1000-7369.2022.05.003]
 QU Zhi,WANG Fen,LI Zhiming,et al.Effect of Erchen decoction on the expression of Hedgehog pathway protein in Lewis lung cancer transplanted tumor[J].,2022,(4):555.[doi:DOI:10.3969/j.issn.1000-7369.2022.05.003]

备注/Memo

备注/Memo:
基金项目:江苏省教育厅优势学科建设工程项目(YSHL0814-227)
更新日期/Last Update: 2024-04-10